Capmatinib rollover study offers continued treatment for cMET-Dependent cancer patients
NCT ID NCT03040973
First seen Nov 01, 2025 · Last updated May 25, 2026 · Updated 23 times
Summary
This study gives patients with advanced cMET-dependent solid tumors continued access to capmatinib, a targeted cancer drug, after completing a previous Novartis-sponsored trial. The main goal is to monitor long-term safety and side effects. About 29 participants who are already benefiting from capmatinib alone or in combination will be followed closely.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS WHICH ARE CMET-DEPENDENT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Novartis Investigative Site
Leuven, 3000, Belgium
-
Novartis Investigative Site
Edmonton, Alberta, T6G 1Z2, Canada
-
Novartis Investigative Site
Shanghai, Shanghai Municipality, 200433, China
-
Novartis Investigative Site
Kunming, Yunnan, 650106, China
-
Novartis Investigative Site
Copenhagen, DK-2100, Denmark
-
Novartis Investigative Site
Dijon, Cote D Or, 21034, France
-
Novartis Investigative Site
Cologne, North Rhine-Westphalia, 50937, Germany
-
Novartis Investigative Site
Hanover, 30625, Germany
-
Novartis Investigative Site
Perugia, PG, 06129, Italy
-
Novartis Investigative Site
Milan, 20141, Italy
-
Novartis Investigative Site
Singapore, 119074, Singapore
-
Novartis Investigative Site
Seoul, 03080, South Korea
-
Novartis Investigative Site
Seoul, 05505, South Korea
-
Novartis Investigative Site
Madrid, 28040, Spain
Conditions
Explore the condition pages connected to this study.